Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.77 |
| ▸ | TACR1 | P25103 | 18/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.67 |
| ▸ | TACR3 | P29371 | 9/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30981004 | 1.00 | GPBAR1 (0.77) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL30981003 | 1.00 | GPBAR1 (0.77) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1872544 | 0.98 | GPBAR1 (0.74) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1872995 | 0.93 | GPBAR1 (0.70) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL337043 | 0.92 | GPBAR1 (0.66) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1871526 | 0.92 | GPBAR1 (0.64) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL27643180 | 0.91 | GPBAR1 (0.65) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1868894 | 0.91 | GPBAR1 (0.63) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL338381 | 0.91 | GPBAR1 (0.63) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1872408 | 0.91 | GPBAR1 (0.63) | GPBAR1TACR1CYP3A4TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473260-B2 | Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814 | KaNDy Therapeutics Limited (GB) | 2025-11-18 | — | — | US | disclosed |
| US-12473260-B2 | Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814 | KaNDy Therapeutics Limited (GB) | 2025-11-18 | — | — | US | disclosed |
| US-20230002322-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002322-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002322-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| WO-2021094247-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021094247-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021094247-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2021-05-20 | — | — | WO | disclosed |
| US-10100030-B2 | Carboxymethyl piperidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-3141541-B1 | CYCLOHEXYL-PYRIDINE DERIVATIVE | KISSEI PHARMACEUTICAL (JP) | 2018-09-26 | — | — | EP | disclosed |
| EP-1309559-B1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-06-07 | — | — | EP | disclosed |
| EP-1643998-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20060030600-A1 | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013050-A1 | DUAL NK1/NK3 ANTAGONISTS AGAINST SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-6770637-B2 | N-(3,5-BIS-TRIFLUOROMETHYL-BENZYL)-6-(4-HYDROXYACETYL-PIPERAZIN-1 -YL)-N-METHYL-4-O-TOLYL-NICOTINAMIDE, FOR EXAMPLE | HOFFMANN-LA ROCHE INC. | 2004-08-03 | — | — | US | disclosed |
| EP-1309559-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-20020040040-A1 | Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors | F. HOFFMAN-LA ROCHE AG (CH) | 2002-04-04 | — | — | US | disclosed |
| WO-2002016324-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | GPBAR1 313/4885TACR1 3/4885CYP3A4 3029/4885 |
| US-20020040040-A1 | Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors | NPSR1, NTSR1, NTSR2 | GPBAR1 430/4885TACR1 4/4885CYP3A4 1861/4885 |
| US-20230002322-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | NT5E, NT5M, NTRK2 | GPBAR1 3570/4885TACR1 174/4885CYP3A4 112/4885 |
| US-20060030600-A1 | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia | TACR2, TACR1, TAC3 | GPBAR1 211/4885TACR1 2/4885CYP3A4 2275/4885 |
| US-10100030-B2 | Carboxymethyl piperidine derivative | TACR1, CYP3A5, CNR1 | GPBAR1 281/4885TACR1 1/4885CYP3A4 5/4885 |
| US-12473260-B2 | Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814 | NT5E, NT5M, NTRK2 | GPBAR1 3309/4885TACR1 168/4885CYP3A4 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.